Hormone receptor-positive breast cancer is the most common form of the disease, accounting for roughly 70 percent of all breast cancer cases worldwide. These tumors depend on estrogen receptor signaling to grow, which is why the backbone of treatment for metastatic disease combines endocrine therapy, typically an aromatase inhibitor that deprives tumors of estrogen, with a cyclin-dependent kinase 4 and 6 inhibitor, a targeted drug that halts cancer cell division. Although this combination has transformed outcomes for many patients, resistance almost inevitably develops, and once the disease progresses, subsequent therapies tend to be less effective and harder to tolerate. Understanding the molecular seeds of that resistance has become one of the most urgent questions in breast cancer medicine.

One of the most important mechanisms of resistance involves the ESR1 gene itself, which encodes the estrogen receptor alpha protein, the principal molecular target of endocrine therapy. Activating mutations in ESR1 are rare at the time of metastatic diagnosis, but they emerge under the selective pressure of aromatase inhibitor treatment, appearing in roughly 40 percent of patients with recurrent disease who have been previously exposed to endocrine therapy. These mutations lock the estrogen receptor into a permanently active state, allowing cancer cells to proliferate even when estrogen is pharmacologically depleted. Crucially, previous research has shown that ESR1 mutations can be detected in circulating tumor DNA, fragments of tumor genetic material drifting in the bloodstream, a median of approximately six months before radiographic progression becomes apparent.

That lead time matters because two landmark clinical trials have demonstrated that acting on it can change patient outcomes. In the phase 3 PADA-1 study, French investigators showed that switching from an aromatase inhibitor to the selective estrogen receptor degrader fulvestrant, while continuing the CDK4/6 inhibitor palbociclib, upon detection of a rising ESR1 mutation in blood significantly improved progression-free survival, reducing the risk of progression by 39 percent. More recently, the phase 3 SERENA-6 trial demonstrated that switching to camizestrant, a next-generation oral selective estrogen receptor degrader, while maintaining a CDK4/6 inhibitor produced a statistically significant and clinically meaningful benefit in an interim analysis. Together, these trials suggest that ESR1 mutation emergence is not merely a biological curiosity but a genuine clinical decision point.

Yet clinical trials are conducted under idealized conditions, with protocol-mandated serial blood testing and standardized treatment algorithms. What actually happens in ordinary oncology practices across the United States, and what the emergence of ESR1 mutations means for patients treated there, has remained far less certain. To address this gap, a research team led by investigators from Emory University, AstraZeneca, and Flatiron Health conducted a retrospective cohort study of patients diagnosed with ER-positive, HER2-negative metastatic breast cancer between January 2018 and June 2024. The database draws deidentified records from both community and academic oncology practices, offering a portrait of care that closely resembles the average patient experience rather than the rarefied environment of a major cancer center.

The scale of the analysis was substantial. Of 8,581 eligible patients, 7,772, or 91 percent, initiated first-line therapy. Among these, only 17 percent had their tumors tested for ESR1 mutations during first-line treatment, revealing that systematic monitoring for this resistance mechanism is far from routine. The median age of patients was 63 years, about 63 percent were White, 75 percent received care in community rather than academic settings, and the median time from the start of first-line therapy to the first ESR1 test was 7.4 months. Treatment patterns were strikingly similar regardless of mutation status: the combination of an aromatase inhibitor with a CDK4/6 inhibitor was the most common first-line regimen overall, used in 55 percent of all tested patients, 58 percent of those with mutations, and 54 percent of those without.

The clinical consequences of mutation detection, however, were anything but similar. To avoid statistical biases that can distort retrospective analyses, the researchers anchored all outcome measurements to the time of the first ESR1 test rather than the start of therapy, and they used propensity score matching to balance the two groups on key covariates including liver metastases, estrogen receptor expression level, age, duration of prior aromatase inhibitor therapy, and menopausal status. After matching, patients with an ESR1 mutation detected at their first test had a median real-world progression-free survival of just 7.7 months, compared with 13.6 months for those without a detected mutation, a hazard ratio of 0.68. Overall survival told the same story: median overall survival was 32.2 months in the mutation group versus a median that had not yet been reached in the non-mutation group, with a hazard ratio of 0.58, corresponding to a substantially elevated risk of death.

The mutation also reshaped the trajectory of care. A dramatically higher share of patients with detected ESR1 mutations, 84 percent compared with 52 percent, went on to receive second-line therapy during follow-up, and those who did were more likely to receive a CDK4/6 inhibitor combined with fulvestrant, or the oral selective estrogen receptor degrader elacestrant, a drug specifically approved for ESR1-mutated disease. In the unmatched analysis, 23 percent of patients with mutations initiated second-line therapy versus 9 percent of those without. These patterns are consistent with the interpretation that ESR1 mutation emergence marks a biologically aggressive, endocrine-resistant phase of disease that shortens the time clinicians must change course, while also reflecting a growing awareness among oncologists that this mutation calls for mutation-directed treatments.

The study’s authors were careful to acknowledge its limitations. Only a minority of patients were tested at all, and the reasons for testing were unknown, meaning the tested population may not represent all patients with metastatic disease. Testing in routine practice often occurs as part of broader genomic panels searching for actionable alterations in genes such as BRCA1, BRCA2, PIK3CA, AKT1, and PTEN, rather than as longitudinal ESR1 monitoring, and the mix of tissue-based and blood-based assays from different commercial vendors introduces variability in sensitivity that could have caused misclassification. Additionally, real-world progression, defined by clinician documentation rather than standardized RECIST imaging criteria, may not perfectly align with trial endpoints, and residual confounding cannot be excluded despite careful matching. Only about 14 percent of all first-line patients could be included in the survival analyses, raising questions about generalizability.

Even with these caveats, the real-world progression-free survival of 7.7 months following mutation detection closely mirrors the 9.2 months observed in the control arm of SERENA-6, where patients with emerging mutations remained on their original aromatase inhibitor and CDK4/6 inhibitor combination. That convergence between randomized trial data and observational practice is striking: it suggests that patients whose ESR1 mutations are detected but left unaddressed fare just as poorly in the community as they did in trial control arms, while trial patients whose therapy was switched fared better. The message for oncology is becoming difficult to ignore. ESR1 mutation emergence defines a clinically vulnerable, pre-progression window of roughly six to nine months, and the tools to exploit that window, liquid biopsy monitoring and next-generation estrogen receptor degraders, now exist. The remaining challenge, the study’s authors conclude, is figuring out how to weave systematic ESR1 surveillance and timely treatment modification into the everyday fabric of cancer care, so that the warning sign carried in a patient’s bloodstream is never missed.

Subject of Research: Real-world treatment patterns and outcomes of emerging ESR1-mutated ER-positive metastatic breast cancer in the United States.

Article Title: Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024

Article References: Meisel, J. L., Chen, C., Kris, A., Ru, M., Pham, T., & Roose, J. (2026). Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024. Breast Cancer Research and Treatment, 219(2), Article 9. https://doi.org/10.1007/s10549-026-08061-w

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08061-w

Keywords: ESR1 mutations, metastatic breast cancer, endocrine resistance, ER-positive HER2-negative, circulating tumor DNA, CDK4/6 inhibitors, aromatase inhibitors, selective estrogen receptor degraders, real-world evidence, progression-free survival, SERENA-6, PADA-1

The clinical investigation, known as the SERENA-6 trial, was published on June 1, 2025, in the prestigious New England Journal of Medicine and presented simultaneously at the American Society for Clinical Oncology’s annual conference. Conducted across numerous leading medical centers throughout Europe, East Asia, and the United States—including prominent institutions affiliated with Weill Cornell Medicine—the trial represents one of the first robust demonstrations of how liquid biopsy-guided treatment adjustments improve outcomes for patients battling estrogen receptor-positive (ER-positive), HER2 receptor-negative breast cancer.

Liquid biopsy technology, which monitors circulating tumor DNA (ctDNA) fragments shed from malignant cells into the bloodstream, provides a minimally invasive window into tumor genetics and dynamics. By detecting the presence of specific mutations earlier and more sensitively than conventional imaging or symptom-based assessments, it empowers clinicians to initiate therapeutic modifications while the tumor burden remains relatively low. Dr. Massimo Cristofanilli of Weill Cornell Medicine, co-author of the study and a recognized expert in cancer precision medicine, emphasized that “intervening sooner, guided by molecular insights from the blood, enables a higher chance of achieving durable tumor control.”

This breakthrough holds particular significance for ER-positive breast cancer, a subtype characterized by tumor cell dependence on estrogen signals mediated through estrogen receptors. While first-line treatment often involves aromatase inhibitors—agents that suppress estrogen synthesis—tumors frequently develop resistance by accruing mutations in the ESR1 gene. These mutations render estrogen receptors constitutively active, sustaining cancer growth despite low estrogen levels, and leading to disease progression.

The SERENA-6 trial was designed to test whether real-time detection of ESR1 gene mutations by liquid biopsy, in patients without visible or symptomatic tumor progression, could trigger an early switch from aromatase inhibitors to a novel investigational drug called camizestrant. Camizestrant acts as a selective estrogen receptor degrader (SERD), effectively reducing the number of estrogen receptors on tumor cells, thereby countering resistance mechanisms and inhibiting tumor proliferation.

Recruitment for this extensive trial spanned 264 clinical sites across 23 countries, enrolling over 3,300 patients with advanced ER-positive, HER2-negative breast cancer. Among them, 315 individuals exhibited detectable ESR1 mutations in their circulating tumor DNA but showed no radiological or clinical signs of tumor progression. These patients were randomized to either discontinue aromatase inhibitors in favor of camizestrant or to continue standard care inclusive of aromatase inhibitor therapy.

The outcome measures revealed a striking difference between the two groups. Patients who switched to camizestrant exhibited a median progression-free survival of 16.0 months, almost doubling the 9.2 months observed in those who remained on standard therapy. This elongation of the non-progression interval indicates that early molecular intervention can effectively delay tumor growth and disease exacerbation.

Moreover, the trial assessed patients’ overall health status and quality of life as secondary endpoints, which are critical factors in advanced cancer management. Those treated with camizestrant enjoyed a median delay in health deterioration of 23.0 months, compared to merely 6.4 months in the control group. This substantial improvement suggests that targeted early treatment not only controls the disease but also preserves patients’ functional status and well-being for prolonged periods.

Safety and tolerability of camizestrant were also carefully evaluated. The drug was well accepted, exhibiting a low incidence of adverse effects leading to treatment discontinuation. These findings support its potential as a viable therapeutic option, with manageable side-effect profiles that may encourage adherence and consistent disease control.

Beyond breast cancer, Dr. Cristofanilli and colleagues highlight the broader implications of their findings for oncology at large. The principle of liquid biopsy-guided intervention could extend to various tumor types that harbor actionable treatment-resistance mutations detectable in circulating tumor DNA. This paradigm shift toward precision oncology promises to optimize therapeutic timing and selection across cancer care.

The SERENA-6 study not only reinforces the utility of liquid biopsies as a noninvasive diagnostic and monitoring tool but also pioneers a treatment algorithm where molecular changes uncovered in blood tests prompt preemptive therapeutic switches. This approach stands to revolutionize clinical practice by circumventing the traditional reliance on imaging and symptomatology, which often detect disease progression too late to confer significant clinical benefit.

By integrating genomic insights into routine patient monitoring, oncologists may be able to tailor therapy dynamically, intercepting the evolution of drug resistance and rendering the management of metastatic breast cancer more effective and patient-centered. As liquid biopsy assays continue to improve in sensitivity and accessibility, their incorporation into standard care protocols is increasingly feasible, signaling a new era in cancer treatment personalization.

Future research is anticipated to expand on these findings by exploring other novel agents suitable for early intervention based on liquid biopsy results, as well as investigating resistance mechanisms that emerge during subsequent lines of therapy. The ongoing refinement of these strategies will be vital to fully harness the promise of precision medicine in oncology.

In conclusion, the SERENA-6 trial establishes liquid biopsy-guided therapeutic switching as a powerful tool in prolonging tumor control and maintaining quality of life for patients with ER-positive, HER2-negative advanced breast cancer. This advancement underscores the transformative impact of integrating molecular diagnostics into clinical decision-making and heralds a future where cancer care is increasingly proactive, personalized, and precise.

Subject of Research: Advanced Breast Cancer; Liquid Biopsy; ESR1 Mutation; Treatment Resistance; Precision Oncology

Article Title: Liquid Biopsy-Guided Treatment Switching Significantly Extends Tumor Control in Advanced ER-Positive Breast Cancer: Results from the SERENA-6 Trial

News Publication Date: 1-Jun-2025

Web References: Not provided

References: New England Journal of Medicine, June 1, 2025; SERENA-6 Clinical Trial Data

Image Credits: Not provided

Keywords: Liquid Biopsy, Breast Cancer, ESR1 Mutation, Aromatase Inhibitors, Camizestrant, Precision Medicine, Treatment Resistance, ER-Positive Breast Cancer